Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb proof of concept trial investigating the effects of GBT-440 on oxygen saturation in patients with idiopathic pulmonary fibrosis (IPF)

Next Previous
Trial Profile

A phase IIb proof of concept trial investigating the effects of GBT-440 on oxygen saturation in patients with idiopathic pulmonary fibrosis (IPF)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Oct 2017 Status changed from planning to withdrawn prior to enrolment according to a Global Blood Therapeutics media release.
    • 23 Oct 2017 According to a company media release, Global Blood Therapeutics has announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies, including a Phase 1 study in healthy volunteers called Basecamp and two Phase 2a studies in patients with IPF called GBT440-006 and ZEPHYR.
    • 05 Apr 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top